BiomX Inc. COmmon Stock
Key Metrics
Market Snapshot
About
BiomX Inc. COmmon Stock (PHGE) is a clinical-stage biopharmaceutical company based in Dover, Delaware, and founded in 2015. It is known for developing phage-based therapies, an approach that uses natural and engineered phage technologies to target and destroy specific harmful bacteria linked to chronic diseases.
The company pursues two main treatment strategies. The first is fixed cocktail therapy, where a single product contains a set number of selected phages chosen to cover a range of bacterial strains. The second is personalized therapy, in which BiomX builds a large library of phages and then matches individual optimal phages to the needs of a particular patient. This combination lets the company address bacterial infections both with standardized products and with tailored treatments.
BiomX has advanced specific candidates through clinical testing. BX011 is a fixed multi-phage cocktail being studied in a Phase 2a trial for diabetic foot infections. BX211 is a phage therapy in a Phase 2 trial aimed at diabetic foot osteomyelitis, a bone infection that can affect people with diabetes. Both programs reflect the company's focus on conditions where harmful bacteria play a central role and where existing options can fall short.
As a clinical-stage developer, BiomX Inc. is working to move these experimental therapies through the stages of testing required before any potential approval and broader use. Its work sits at the intersection of microbiology and drug development, applying phage science to chronic and difficult-to-treat bacterial conditions rather than relying on conventional antibiotics alone.